Humana Inc. (NYSE:HUM) Stock Holdings Decreased by Invesco Ltd.

Key Points

• Invesco Ltd. reduced its stake in Humana Inc. by 6.2% in the first quarter, owning 2,249,241 shares valued at approximately $595 million.
• Humana reported quarterly earnings of $6.27 EPS, missing estimates by $0.05, with a revenue of $32.39 billion, exceeding forecasts.
• Seventeen analysts have rated Humana with a "hold" rating, while seven issued a "buy" rating, with an average price target of $281.62.

Invesco Ltd. reduced its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 6.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,249,241 shares of the insurance provider's stock after selling 148,567 shares during the period. Invesco Ltd. owned about 1.86% of Humana worth $595,149,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Frank Rimerman Advisors LLC grew its holdings in Humana by 17.2% during the 1st quarter. Frank Rimerman Advisors LLC now owns 1,732 shares of the insurance provider's stock worth $458,000 after acquiring an additional 254 shares in the last quarter. MUFG Securities EMEA plc bought a new position in shares of Humana in the 1st quarter worth about $9,790,000. Cynosure Group LLC lifted its position in shares of Humana by 11.6% in the 1st quarter. Cynosure Group LLC now owns 1,317 shares of the insurance provider's stock worth $348,000 after buying an additional 137 shares during the last quarter. Townsquare Capital LLC lifted its position in shares of Humana by 2.8% in the 1st quarter. Townsquare Capital LLC now owns 2,255 shares of the insurance provider's stock worth $597,000 after buying an additional 61 shares during the last quarter. Finally, Zions Bancorporation National Association UT bought a new position in shares of Humana in the 1st quarter worth about $37,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HUM has been the topic of a number of recent research reports. Robert W. Baird reduced their price target on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Piper Sandler reduced their price target on shares of Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research report on Thursday, July 31st. Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 price target on shares of Humana in a research report on Thursday, May 1st. Argus restated a "hold" rating and issued a $281.99 price target on shares of Humana in a research report on Thursday. Finally, Morgan Stanley cut their price objective on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 31st. Eighteen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $281.45.

Humana Price Performance

Shares of HUM traded up $0.51 during mid-day trading on Thursday, hitting $282.50. The company's stock had a trading volume of 560,653 shares, compared to its average volume of 1,732,828. The firm has a 50-day moving average price of $240.47 and a 200 day moving average price of $254.05. The stock has a market capitalization of $33.98 billion, a price-to-earnings ratio of 21.68, a PEG ratio of 1.62 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $382.72.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The firm had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. The business's revenue was up 9.6% on a year-over-year basis. During the same period last year, the business earned $6.96 earnings per share. On average, research analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.